Skip to main content
Lippincott Open Access logoLink to Lippincott Open Access
. 2026 Sep 18;33(1):174–181. doi: 10.1097/PHH.0000000000002487

Cost Savings Modeling of Integrated Telehealth Services for Hepatitis C Virus Infection—Cherokee Nation, 2016–2020

Jorge Mera 1,✉, Molly Feder 1, Jeri Sawyer 1, Gretchen Greene 1, Ashley Wirth 1, Jessica Leston 1
PMCID: PMC13758913  PMID: 42758553

ABSTRACT

Context:

American Indian and Alaska Native (AI/AN) people experience the highest rates of hepatitis C virus (HCV) infection and HCV-related mortality in the United States. However, access to HCV care remains limited in many tribal and rural communities. Telehealth models such as the Extension for Community Healthcare Outcomes (ECHO) have been used to expand access by supporting primary care providers in delivering complex treatments locally.

Objectives:

To assess the cost savings of implementing Cherokee Nation Health Services' (CNHS) HCV ECHO program compared with conventional, specialist-based care.

Design:

This modeling analysis compared estimated costs of conventional care and ECHO-supported care using CNHS financial records, internal accounting data, and publicly available cost estimates. Modeling methods are provided in more comprehensive detail in the appendix. HCV prevalence, treatment initiation, and sustained virologic response outcomes were derived from deidentified CNHS electronic medical record data from 2016 to 2020. Demographic projections were based on US Census data for the Cherokee Oklahoma Tribal Statistical Area to model HCV treatment outcomes by age and sex through 2040.

Study timeframe:

ECHO program between 2016 and 2020.

Main outcome measure:

Estimated cost per patient and projected cumulative cost savings over 10- and 20-year horizons.

Setting:

CNHS is the largest tribally operated health system in the United States, serving a predominantly AI/AN population in rural Oklahoma.

Participants:

Modeled patient population with diagnosed HCV infection in the CNHS service area. The average number of patients based on the CNHS data between 2016 and 2019 was 185, which was used as the 2010 base for the model.

Intervention:

Implementation of an HCV ECHO program beginning in 2014 to decentralize HCV treatment to primary care providers through case-based telehealth consultation and guided mentorship.

Results:

HCV care delivered via ECHO cost 69% less per patient than conventional specialist care ($1412 vs. $4534), yielding projected savings of $6.3 million over 10 years and nearly $10 million over 20 years.

Conclusions:

The CNHS HCV ECHO program demonstrates that telehealth-based models can deliver substantial cost savings while improving access to specialty-level care in rural and AI/AN communities.

KEY WORDS: American Indian and Alaska Native, decentralized care, ECHO model / Extension for Community Healthcare, hepatitis C virus, primary care–based HCV treatment

Introduction

American Indian and Alaska Native (AI/AN) people are disproportionately affected by hepatitis C virus (HCV) infection, with the highest rate of chronic HCV infection (68.9 per 100 000) and HCV-related mortality (9.99 per 100 000) compared with other races in the United States.1 Telehealth programs using the Extension for Community Healthcare Outcomes (ECHO) Model® have been shown to expand access to HCV care, especially in underserved communities.2,3 In 2014, Cherokee Nation Health Services (CNHS), the largest tribally operated health system in the United States, adopted the Indian Country ECHO's multidisciplinary model to support whole-person, primary care–based HCV treatment. Although the ECHO model is designed to support whole-person care, this evaluation was limited to direct HCV service costs. This study assessed the cost savings of implementing CNHS’ HCV ECHO program compared with conventional specialist care (Supplemental Digital Content, https://links.lww.com/JPHMP/B743).

Background

ECHO programs, through case-based, HIPAA-compliant telehealth support across health care facilities, enhance primary care treatment of underserved patients with complex and often stigmatized medical conditions.4 Through the guided mentoring and learning relationships that develop between all participants and medical specialists, ECHO programs improve access to effective care for conditions like HCV by enhancing community practitioners' and professionals' skills, knowledge, and support at primary care sites where specialty providers may not be available, including in rural settings.5 Treatment at the primary care level is an important element of access to care in rural and remote settings, where travel time and cost to referred care coupled with limited specialist availability can be important barriers to care. Recent research on this topic has called for better economic analysis of telehealth programs comparing the effectiveness of different modalities, and also research on the improving access to underserved populations6 Cherokee Nation's network of health centers (CNHS) is the largest tribally operated health system in the United States, receiving over 1.6 million patient visits in 2023.7 The Board Cherokee Nation Institutional Review Board approved this cost-savings analysis proposal on October 13, 2021.

Methods

This analysis modeled the comparative costs of 2 HCV care delivery scenarios within CNHS: conventional specialist–based care and ECHO-supported primary care. The model used CNHS cost and program data, along with US Census–based demographic projections, to estimate population trends, HCV prevalence, and treatment outcomes through 2040. The analysis included 3 components: (1) estimation of program costs for conventional and ECHO-based care; (2) demographic projections of the CNHS service area population; and (3) application of HCV prevalence and treatment outcomes to forecast costs and savings over time. Costs were calculated per patient and for the total projected population, assuming equal treatment efficacy across both scenarios. An overview of the analysis process is provided in Figure 1.

FIGURE 1.

FIGURE 1

Analysis process chart.

Cost modeling of ECHO and conventional care

The total cost of HCV care for both scenarios was calculated annually and compared. Conservative estimates for conventional care costs were based on ranges developed from publicly available data sources. Laboratory and staffing costs for ECHO were estimated using internal accounting and billing data. Staffing costs were prorated based on time spent on ECHO-related duties. The costs and sources of both scenarios are outlined in Table 1 and related footnotes.

TABLE 1.

Estimated Annual per-Patient Program Cost of HCV Care for ECHO and Conventional Care, Cherokee Nation Health Services, 2022

Cost Component Conventional Care Costs ECHO Costs
Program
 Administration & equipmenta N/A $1
Personnel
ECHO directorb N/A $313
 Nursesb N/A $36
 Primary care providersb N/A $74
 Pharmacistsb N/A $57
 ECHO coordinatorsb N/A $19
 Case managersc N/A $238
 Community health workersc N/A $82
Specialist related costs
 Specialist visitsd $1200 N/A
 Lost time from worke $640 N/A
 Travel to specialistsfb $168 N/A
Testing for HCV
 HCV Ab w/Rfxg $44i $6h
 HCV RNA PCR quantj $1300i $425h
 HCV genotypeg $1,090k $130h
 NS5A resistance GT1l $92m $37h
 NS5B resistance GT1l $92m $23h
TOTAL (may not sum because of rounding) $4534 ($2599 with internal laboratory costs) $1412
Potential total cost savings (conventional care—ECHO) $3122 ($1187 with internal laboratory costs)
a

Includes technology equipment (computer and IT time).

b

Salary times share of HCV-related work.

c

Annual salary given 100% of work is HCV-related; case managers primarily support medication procurement. This case manager cost would be eliminated with on-site medications.

d

Cost per patient to visit a specialist, including 4 visits estimated at $300 per visit, estimated and rounded based on several sources, including Debt.org and Agency for Healthcare Research and Quality, Medical Expenditure Panel Survey, Household Component, 2016.

e

Cost per patient, assuming 1 full day of work lost at an average of $20 hourly wage and the same number of visits as with the ECHO scenario, estimated based on interviews with CNHS staff.

f

Cost per patient, estimated using Google Maps to show the distance between Tahlequah, OK, and Tulsa, OK, the nearest major surrounding city at the 2021 IRS standard mileage rate.

g

Assumes 1 test per patient.

h

Based on sent out laboratory costs from CNHS in August 2022.

i

Estimated using DxSaver.com, (https://www.dxsaver.com/hep-c-test-cost/), accessed on August 24, 2022.

j

Assumes 5 tests per patient.

k

Estimated using Biotechnology Healthcare, 2005, HCV Testing Cost-Effective Alternative, and adjusted to 2022 dollars.

l

Assumes 5 percent of patients, only 1 or the other test is used per patient.

m

Calculation based on the relationship between the HCV RNA PCR quant for ECHO versus conventional (based on research) and applying that relationship to the NS5A and NS5B resistance GT1 ECHO costs (and averaging the 2 as only 1 is used if needed).

The analysis assumes equal proportions of patients treated with sustained virologic response (SVR) and with adverse outcomes from delayed or no HCV treatment. SVR is achieved when the hepatitis C virus is not detected in the blood 12 weeks or more after treatment completion.8 The only quantifiable measure of benefit included in this analysis was cost savings between the 2 scenarios. Costs in both scenarios were assessed regardless of the payor. To determine a population denominator, a cohort-component model (CCM) was used to project the population of the Cherokee Oklahoma Tribal Statistical Area (OTSA) population as an approximation of the CNHS service area from 2010 to 2040.

Demographic projection data sources

The 2010 CNHS service population (Health Service Area) is estimated at the same level as the 2010 Decennial Census population for the OTSA for American Indian/Alaska Native alone or in combination with 1 or more races (AI/AN AOIC). The base population for the population and HCV treatment projections were obtained from the 2010 Census SF2 PCT3 data file, by age and sex for AI/AN AOIC. This was the most complete, current, publicly available data at the time the study was initiated. Fertility rates for the population projection model are calculated from birth rates by mother's age (5-year cohorts for ages 10–54) for AI/AN in 14 Oklahoma Counties.9 Fertility rates are then projected forward to decline to a total fertility rate of 2.15 by 2040, with rate of decline based partially on Census projections.10 Initial survival rates for the population projection model are based on IHS life tables for the Oklahoma Area.11 These are then projected forward to increase through time, similar to Census projected rates of change.10 Net-migration each 5-year period is assumed to be 0.7 percent, which is approximately 1000 in-migrating to the service area per year. This is a conservative but reasonable estimate. The net-migration pattern for the population projection model is estimated using a forward survival method calculated between 2000 and 2010. These population data were used as the basis for a forecast of health outcomes.

HCV prevalence and treatment forecasting

The population projection model was used as the basis to develop a forecast of health outcomes. Data related to HCV prevalence were applied to the population projection model by sex and age cohort to estimate the number of people with HCV in the Cherokee population. The share of the CNHS Service Area population with HCV expected to initiate and complete treatment was estimated based on previously published data and deidentified CNHS EMR data analysis for patients with a record of HCV antibody or RNA test from 2015 to 2021.12,13 Variables of interest for the model included HCV RNA tests and results, treatment initiation and completion, and SVR. Patient age and sex were also extracted to estimate the HCV prevalence, treatment initiation and completion rates, and SVR rates by age and sex cohort for the CNHS Service Area population. Declines in HCV prevalence were estimated based on previously published estimates by Mera et al.14 Specific assumptions are included in this analysis. Treatment costs are assumed to be identical for both scenarios, so no drug treatment costs are included. SVR rates are also assumed to be equal, making the cost savings extremely conservative, or lower than what would happen. There are additional benefits from ECHO such as reduced patient attrition and lower long-term medical costs because of earlier treatment. For this initial analysis, the conservative assumption is made; however, the additional benefits from reduced patient attrition and lower long-term medical costs are a topic for further research. Suffice to say the current analysis is at the low end of the ECHO cost savings because of this assumption.

Population projection model

A CCM divides a population into age and sex cohorts and then applies the components of change—births, deaths, and net migration—to each cohort.15 The method is initiated with a base-year population that is divided into 5-year age cohorts for each sex. These groups are then hypothetically aged 5 years, subtracting a small percentage assumed to have died in the 5-year period. Mortality rates are used to estimate the deaths that might occur in each age/sex cohort. The number of babies to be added to the population in each 5-year period is estimated in a similar fashion by applying fertility rates to females in the childbearing-age cohorts. Finally, rates of in- and out-migration are also applied to each age/sex cohort to simulate the movement onto and off of the OTSA through time. The total number of people who move in, minus the total number of people who move out in each period, is known as net migration. Each of these steps are performed for each 5-year period between 2010 and 2040. The population projection model is used as the basis to develop a forecast of health outcomes through 2040. Data related to HCV prevalence are applied to the population projection model by sex and age cohort to estimate the number of people with HCV in the Cherokee population. The share of the population with HCV expected to receive treatment and complete treatment is estimated based on the treatment variables from Cherokee data. Rates of SVR are used to forecast the populations cured during each time period.

Results

The total estimated costs per patient per year were $4534 for conventional care and $1412 with ECHO (Table 1). This represents a cost savings of 69% or $3122 per patient with ECHO. The difference in laboratory and testing costs represented $1935 (62%) of the total savings per patient. If conventional laboratory and testing costs were performed on-site instead of with specialists, the total estimated cost per patient for conventional care would decrease to $2599 but remain higher than ECHO costs at $1412 per patient.

In 2020, conventional care program costs were estimated at over $915,000 per year, whereas ECHO costs were estimated at just over $285,000 (Table 2). By 2040, considering both a growing population and a declining HCV prevalence, conventional care costs were projected at nearly $355,000 per year, and ECHO costs were projected at just over $110,000.

TABLE 2.

Five-Year Average Annual Costs and Cost-Savings, Results, Cherokee Nation Health Services, 2020–2040

2020 2025 2030 2035 2040
ECHO costs $285,150 $244,639 $189,893 $146,513 $110,484
Conventional care costs with outside laboratories (with internal laboratory costs) $915,856 ($524,913) $785,741 ($450,339) $609,907 ($349,562) $470,575 ($269,705) $354,858 ($203,383)
Cost savings (with internal laboratory costs) $630,706 ($239,763) $541,102 ($205,700) $420,014 ($159,668) $324,062 ($123,192) $244,373 ($92,899)
Number of patients 202 173 135 104 78

From a cost-savings perspective, ECHO costs less than half the price of conventional care at each point in the future, estimated at $630,700 less than conventional care in 2020, $420,000 less in 2030, and $244,000 less in 2040, with cost-savings decreasing over time as HCV declines (Table 2). Assuming on-site laboratory activities for conventional care, ECHO cost savings are reduced but remain substantial, with ECHO costs estimated at nearly $240,000 less than conventional care in 2020, almost $160,000 less in 2030, and almost $93,000 less in 2040.

Assuming constant 2022 dollars (ie, no inflation) and equal rates of SVR from both scenarios, the cumulative cost over the first 10 years of conventional care totals $9.1 million, and ECHO totals $2.8 million, for a total savings of $6.3 million with ECHO (Fig. 2). Over 20 years, the cumulative costs total nearly $14.3 million for conventional care and $4.4 million for ECHO, leading to an expected cost-savings of nearly $10 million. This corresponds with nearly 2000 cumulative patients over the first 10 years (Fig. 3) and almost 3000 cumulative patients over 20 years.

FIGURE 2.

FIGURE 2

Estimated cumulative costs of HCV care via ECHO and conventional care (with both outside and internal laboratory costs), Cherokee Nation Health Services, 2020–2040.

FIGURE 3.

FIGURE 3

Estimated cumulative number of patients, Cherokee Nation Health Services, 2020–2040.

Discussion

In this analysis, ECHO realized a 69% cost-savings per patient with conventional care. Over a 20-year timespan, ECHO was projected to save nearly $10 million in HCV care–related costs in the CNHS Service Area. These findings demonstrate that investing in an HCV ECHO program in the Cherokee Nation has led, and will continue to lead, to substantial cost savings for HCV care.

To the authors' knowledge, no similar cost savings analyses of ECHO programs have been conducted in Indian Country. However, this study aligns with existing literature on the economic benefits of HCV ECHO programs for underserved communities.16

This study has 4 key limitations. First, modeling did not include drug treatment costs, as the actual treatment cost was assumed to be identical in both scenarios. If there were cost-savings for HCV Direct-Acting antivirals in the conventional or ECHO care models, this could affect cost-savings results. Second, SVR rates were assumed to be equal in both scenarios. If there are variations between scenarios, the cost savings outcomes may be affected. Third, this study did not include additional potential benefits of ECHO, such as reduced patient attrition or lower long-term medical system costs associated with earlier treatment, which likely underestimates the total cost savings. Behavioral health integration, a component of Indian Country ECHO programs, was also not assessed, as it was not a component of the conventional care model. However, separate analyses suggest that including behavioral health care still would have led to cost savings with ECHO. Finally, some of the estimates used for the conventional care model were roughly calculated based on ranges found through online sources. Other limitations that were not explored at all could include additional costs that were not accounted for. In addition to potential others, some examples could include childcare, insurance premiums, and other indirect expenses.

Implementing the ECHO model for HCV care within CNHS resulted in substantial cost savings and expanded access to treatment in a rural AI/AN community. ECHO's impact extends beyond economic value; by building capacity within primary care settings, it strengthens local health systems, improves access to specialty care, and supports broader goals for equity. Funding and sustainability mechanisms should be considered during program development to enable ongoing support for ECHO. Future studies would enhance understanding of ECHO's economic value, including unquantified benefits, and explore replicability in additional access-limited settings. Adoption of ECHO and similar tele-health supported models could accelerate progress toward national HCV elimination targets, particularly in rural and underserved populations. Future work should evaluate how telehealth-based HCV programs could integrate behavioral health, medication access, and chronic disease management to amplify both clinical and economic benefits.

Implications for Policy and Practice

  • ■ Telehealth-based care models can produce major cost savings while expanding access to treatment for chronic infectious diseases in underserved communities.

  • ■ Within CNHS, the ECHO model reduced the cost of HCV care by more than two-thirds compared with conventional specialist care.

  • ■ These findings have broad implications for tribal, rural, and other access-limited health systems.

  • ■ Integrating ECHO into primary care settings can improve treatment access and outcomes by bringing effective, guideline-based, specialist-supported care closer to patients’ medical homes.

  • ■ As tribal and other rural systems move toward HCV elimination goals, sustainable funding mechanisms and continued evaluation of telehealth models will be essential for maintaining and scaling their impact on population health and health system efficiency.

Supplementary Material

phh-33-174-s001.docx (657.5KB, docx)

Footnotes

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.JPHMP.com).

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. J. Mera reports institutional grant support from the Indian Health Service, Substance Abuse and Mental Health Disorders Services Administration, AbbVie Pharmaceuticals, and Gilead Foundation, and honoraria from AbbVie Pharmaceuticals and Cepheid. J. Mera also reports consulting fees from Oklahoma State University and the Northwest Portland Area Indian Health Board for Hepatitis C ECHO consultation. No other potential conflicts of interest were disclosed.

Acknowledgments: David Stephens, Brigg Reilley, Whitney Essex, Ami Sams, Dwayne David, Gaye Wheeler, Wendy Nakatsukasa-Ono, Amanda Winters, Nneoma Nwobilor, and Project ECHO at the University of New Mexico.

Contributor Information

Molly Feder, Email: mfeder@cardeaservices.org.

Jeri Sawyer, Email: jsawyer@greeneeconomics.com.

Gretchen Greene, Email: ggreene@greeneeconomics.com.

Ashley Wirth, Email: ashl10wirth@gmail.com.

References

  • 1.CDC. Viral Hepatitis Surveillance Report—United States, 2021. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. Available at: https://www.cdc.gov/hepatitis/statistics/2021surveillance/hepatitis-c/table-3.8.htm [Google Scholar]
  • 2.Arora S, Thornton K. Novel models of hepatitis C virus care delivery: telemedicine, project ECHO, and integrative care. Clin Liver Dis. 2020;16(1):5–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199–2207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Arora S, Geppert CM, Kalishman S, et al. Academic health center management of chronic diseases through knowledge networks: project ECHO. Acad Med. 2007;82(2):154–160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Zhou C, Crawford A, Serhal E, Kurdyak P, Sockalingam S. The impact of project ECHO on participant and patient outcomes: a systematic review. Acad Med. 2016;91(10):1439–1461. [DOI] [PubMed] [Google Scholar]
  • 6.Gujral K, illarmo S, Jacobs JC, Wagner TH. The economics of telehealth: an overview. Telemed e-Health. 2025;31(9):1074–1095. [DOI] [PubMed] [Google Scholar]
  • 7.Cherokee Nation. Cherokee Nation Health Services 2023 Annual Report. Cherokee Nation Health Services. https://www.cherokee.org/media/rynjpvrd/health-services-annual-report-calendar-year-2023_apr-2-2.pdf [Google Scholar]
  • 8.HCV Guidance. Recommendations for testing, managing, and treating hepatitis C. American Association for the Study of Liver Diseases. 2013. [Google Scholar]
  • 9.Oklahoma State Department of Health. Center for health statistics, health Care Information, vital statistics 2010 to 2015, on Oklahoma statistics on health available for Everyone (OK2SHARE). Available at: http://www.health.ok.gov/ok2shareon06MAY2021. Accessed May 06, 2021.
  • 10.U.S. Census Bureau. Methodology and Assumptions for the Population Projections of the United States: 1999 to 2100, Population Division Working Paper No. 38. January 13, 2000.
  • 11.United States Department of Health and Human Services Indian Health Service. Life Expectancy American Indians and Alaska Natives Data Years: 2007-2009; 2014. Released December. [Google Scholar]
  • 12.Mera J, Vellozzi C, Hariri S, et al. Identification and clinical management of persons with chronic hepatitis C virus infection — cherokee Nation, 2012–2015. Morb Mortal Wkly Rep. 2016;65(18):461–466. [DOI] [PubMed] [Google Scholar]
  • 13.Mera J, Williams MB, Essex W, et al. Evaluation of the Cherokee Nation Hepatitis C Virus Elimination Program in the first 22 months of implementation. JAMA Netw Open. 2020;3(12):e2030427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Mera J, Essex W, Feder M, Razavi H, Razavi-Shearer D. The elimination of hepatitis C in the Cherokee Nation: the impact of harm reduction. J Hepatol. 2022;77(Suppl):S226–S227. [Google Scholar]
  • 15.Pittenger DB. Projecting State and Local Populations. Cambridge, MA: Ballinger Publishing Company; 1976. [Google Scholar]
  • 16.Wong JB, Thornton KA, Carroll C, Arora S. Cost-effectiveness of hepatitis C treatment by primary care providers supports by the extension for community healthcare outcomes (ECHO) model. Hepatology. 2013;58(S1):330A. November 2013: The 64th Annual Meeting of the American Association for the Study of Liver Diseases. Abstract 245. [Google Scholar]

Articles from Journal of Public Health Management and Practice are provided here courtesy of Wolters Kluwer Health

RESOURCES